A Multicenter, Randomized, Double-blind, Single-dummy, positive drug and placebo-controlled, Parallel Group, Phase 2a Study to Evaluate the Efficacy and Safety of Hemay005 in Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Sputum biomarkers
Timeframe: Change from baseline to week 4
Sputum cell count
Timeframe: Change from baseline to week 4
Blood Biomarkers
Timeframe: Change from baseline to week 4